ArticleEuropean journal of nuclear medicine and molecular imaging2007
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Article in European journal of nuclear medicine and molecular imaging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Repeatability of quantitativeEuropean journal of nuclear medicine and molecular imaging · 2018Pooled it
- Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015Trial
- Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.Molecular imaging and biology · 2014Trial
- Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.Molecular imaging and biology · 2013Trial
- Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.European journal of nuclear medicine and molecular imaging · 2012Trial
- Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.Breast cancer research and treatment · 2011Trial
- Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time.Cancer biotherapy & radiopharmaceuticals · 2010Trial
- The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.European radiology · 2009Trial
- Observational
- A PET probe targeting polyamine transport system for precise tumor diagnosis and therapy.Asian journal of pharmaceutical sciences · 2024Article
- Repeatability ofEJNMMI research · 2024Article
- Metabolic Imaging as a Tool to Characterize Chemoresistance and Guide Therapy in Triple-Negative Breast Cancer (TNBC).Molecular cancer research : MCR · 2023Article
- Article
- Comparison ofTomography (Ann Arbor, Mich.) · 2022Article
- Role of 3'-Deoxy-3'-[JTO clinical and research reports · 2022Article
- Novel applications of molecular imaging to guide breast cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Review
- Prospective comparison of early interimBMC cancer · 2021Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
purpose3'-deoxy-3'-[18F]fluorothymidine positron emission tomography ([18F]FLT-PET) has been developed for imaging cell proliferation and findings correlate strongly with the Ki-67 labelling index in breast cancer. The aims of this pilot study were to define objective criteria for [18F]FLT response and to examine whether [18F]FLT-PET can be used to quantify early response of breast cancer to chemotherapy.
methodsSeventeen discrete lesions in 13 patients with stage II-IV breast cancer were scanned prior to and at 1 week after treatment with combination 5-fluorouracil, epirubicin and cyclophosphamide (FEC) chemotherapy. The uptake at 90 min (SUV90) and irreversible trapping (Ki) of [18F]FLT were calculated for each tumour. The reproducibility of [18F]FLT-PET was determined in nine discrete lesions from eight patients who were scanned twice before chemotherapy. Clinical response was assessed at 60 days after commencing FEC.
resultsAll tumours showed [18F]FLT uptake and this was reproducible in serial measurements (SD of mean % difference=10.5% and 15.1%, for SUV90 and Ki, respectively; test-retest correlation coefficient>or=0.97). Six patients had a significant clinical response (complete or partial) at day 60; these patients also had a significant reduction in [18F]FLT uptake at 1 week. Decreases in Ki and SUV90 at 1 week discriminated between clinical response and stable disease (p=0.022 for both parameters). In three patients with multiple lesions there was a mixed [18F]FLT response in primary tumours and metastases. [18F]FLT response generally preceded tumour size changes.
conclusion[18F]FLT-PET can detect changes in breast cancer proliferation at 1 week after FEC chemotherapy.
Indexed as
Identifiers
17333178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.